Scroll for more

news

featured

Recent

Apr 25, 2017 articles

A British tech unicorn is trying to cure Alzheimer's and ALS with artificial intelligence

Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.

Feb 21, 2017 articles

Bold claims for AI are hard to compute for economists

The Financial Times takes a look at the work we’re doing at BenevolentAI to “revolutionise medical research” after speaking to Co-Founder and Director, Ken Mulvany.